{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:26:26Z","timestamp":1793064386362,"version":"4.5.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Prospective data from 2 phase 2 trials showed favorable wound complication rates and promising local control after a reduced preoperative radiotherapy dose for myxoid liposarcoma (MLS). However, long-term follow-up data are currently lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the efficacy and toxicity profile of a reduced preoperative radiotherapy dose in patients with MLS with long-term follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>The Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma (DOREMY) trial is a prospective, single-group, phase 2 nonrandomized clinical trial conducted in 9 tertiary sarcoma centers in Europe and the US. Eligible patients were adults with biopsy-proven and translocation-confirmed localized MLS of the trunk or extremity who were enrolled from November 24, 2010, to May 14, 2020. Data were analyzed from January to December 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Preoperative radiotherapy to a reduced dose of 36 Gy in once-daily 2-Gy fractions followed by resection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Long-term local recurrence-free survival, progression-free survival, disease-specific survival, overall survival, and late toxic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety patients (mean [SD] age, 47 [13.1] years; 50 [56%] male) were included and followed up for a median (IQR) of 66.4 (48.8-87.5) months. Preoperative radiotherapy was delivered according to protocol in all patients. Surgery was not performed in 3 patients (3%) due to intercurrent metastatic disease. Local recurrence-free survival, progression-free survival, disease-specific survival, and overall survival rates at 5 years were 97.4% (95% CI, 93.9%-100%), 81.0% (95% CI, 72.6%-89.4%), 89.5% (95% CI, 82.6%-96.4%), and 88.5% (95% CI, 81.2%-95.8%), respectively. In total, 18 patients (21%) experienced a wound complication, and 14 (16%) required intervention. Any grade 2 or grade 3 late toxic effects were seen among 13 patients (15%) and 3 patients (3%), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>This long-term analysis of the DOREMY nonrandomized clinical trial demonstrated excellent local control and a favorable toxicity profile following dose reduction of preoperative radiotherapy in patients with MLS. These compelling phase 2 findings support adoption of this regimen as an appropriate treatment option through shared decision-making with the patient, given the impracticality of conducting a phase 3 trial for a rare cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02106312\">NCT02106312<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.1577","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:30:15Z","timestamp":1778923815000},"page":"863","source":"Crossref","is-referenced-by-count":1,"title":["Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma"],"prefix":"10.1001","volume":"12","author":[{"given":"Jules","family":"Lansu","sequence":"first","affiliation":[{"name":"Sarcoma Unit, Department of Radiotherapy, Netherlands Cancer Institute, Amsterdam, the Netherlands"},{"name":"Department of Radiotherapy, Dr Bernard Verbeeten Institute, Tilburg, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith V. M. G.","family":"Bov\u00e9e","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e8tra M.","family":"Braam","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha B.","family":"Miah","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Department of Radiotherapy and Physics, The Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind S.","family":"Bruland","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Baldini","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid N.","family":"Scholten","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Department of Radiotherapy, Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Hamming-Vrieze","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Department of Radiotherapy, Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Heukelom","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (Maastro), GROW Research institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette M.","family":"Wiltink","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Department of Radiotherapy, Netherlands Cancer Institute, Amsterdam, the Netherlands"},{"name":"Department of Radiotherapy, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florine","family":"Foppele","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Department of Radiotherapy, Netherlands Cancer Institute, Amsterdam, the Netherlands"},{"name":"Department of Radiotherapy, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan F.","family":"Ubbels","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Groningen University Medical Center, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"van der Noort","sequence":"additional","affiliation":[{"name":"Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick L.","family":"Haas","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Department of Radiotherapy, Netherlands Cancer Institute, Amsterdam, the Netherlands"},{"name":"Department of Radiotherapy, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"cbr260008r1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1200\/JCO.1996.14.3.859","article-title":"Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.","volume":"14","author":"Pisters","year":"1996","journal-title":"J Clin Oncol"},{"issue":"1","key":"cbr260008r2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1200\/JCO.1998.16.1.197","article-title":"Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.","volume":"16","author":"Yang","year":"1998","journal-title":"J Clin Oncol"},{"issue":"11","key":"cbr260008r3","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"cbr260008r4","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3390\/jcm9082471","article-title":"Hypofractionated radiotherapy in locally advanced myxoid liposarcomas of extremities or trunk wall: results of a single-arm prospective clinical trial.","volume":"9","author":"Kosela-Paterczyk","year":"2020","journal-title":"J Clin Med"},{"issue":"14","key":"cbr260008r5","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1002\/cncr.24375","article-title":"Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas.","volume":"115","author":"Chung","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"cbr260008r6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1245\/s10434-011-2127-z","article-title":"Myxoidcell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases.","volume":"19","author":"Moreau","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"cbr260008r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5865","article-title":"Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonrandomized controlled trial.","volume":"7","author":"Lansu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"cbr260008r8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ijrobp.2012.01.062","article-title":"Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where?","volume":"84","author":"Haas","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"cbr260008r9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1667\/RADE-20-00226.1","article-title":"Cellular radiosensitivity of soft tissue sarcoma.","volume":"196","author":"Haas","year":"2021","journal-title":"Radiat Res"},{"issue":"1","key":"cbr260008r10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11864-022-00943-7","article-title":"Preoperative radiation for soft tissue sarcomas: how much is needed?","volume":"23","author":"Ahmed","year":"2022","journal-title":"Curr Treat Options Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2849248\/jamaoncology_lansu_2026_br_260008_1787161709.93145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:02:05Z","timestamp":1787238125000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2849248"}},"subtitle":["The Phase 2 DOREMY Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.1577","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}